Targeting Thyroid Cancer
Program Goal
Thyroid Cancer Newly Detected 2013 (n=60,220)
Follicular Cell Thyroid Cancer Deaths 2013 (n = 1850)
Familial Syndromes
Thyroid Cancer Treatment “Pyramid”
Risk Stratification
RAI-Refractory Disease
Doxorubicin: Single-agent Activity
Doxorubicin +/- Cisplatin
Doxorubicin +/- Cisplatin: Results
Targets in Thyroid Cancer
VEGF and Thyroid Cancer
Sorafenib
Sorafenib University of Pennsylvania
Sorafenib Results University of Pennsylvania
Sorafenib Ohio State
Sorafenib Results Ohio State
Sorafenib Response Rates Ohio State vs Penn
DECISION Study
DECISION Study Results
DECISION Study Response Rates
Lenvatinib (E7080) Background
Lenvatinib Response Rate
Differentiated Thyroid Cancers Phase 2 Studies -- Multitargeted TKIs
Summary of Angiogenesis Inhibition
Genetic Alterations in Thyroid Cancer
Concordance of Genetic Alterations in MAPK but Not PI3K Pathway Oncogenes
Selumetinib (AZD6244)
Selumetinib Response Rate
Impact of Selumetinib on 124I Incorporation
Responses for RAI-Treated Patients
BRAF
Vemurafenib
Vemurafenib Response Rate
Current Studies for BRAF Mutant Thyroid Cancer
Summary of BRAF and MEK targets
Medullary Thyroid Cancer
Presentations of MCT
MTC: Hereditary vs Sporadic?
Hereditary MTC Until Proven Otherwise
Sporadic MTC Frequency of RET Mutations
Vandetanib (ZD6474)
Vandetanib: Randomized Phase 3 Trial
Vandetanib: PFS
Vandetanib: Objective Tumor Assessments
Cabozantinib (XL184)
Cabozantinib: Phase 3 Study Design (EXAM)
Cabozantinib: PFS
Summary of Medullary Thyroid Cancer
Abbreviations
Abbreviations (cont)
Abbreviations (cont)
References
References (cont)
References (cont)
References (cont)
References (cont)
References (cont)
References (cont)